CompletedPhase 3

Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Germany, United Kingdom2,134 participantsStarted 2007-01

Plain-language summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with Hodgkin's lymphoma.

Who can participate

Age range17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically confirmed classical Hodgkin's lymphoma * No lymphocyte-predominant Hodgkin's lymphoma * Fine-needle biopsy not sufficient * No prior treatment for Hodgkin's lymphoma except for recommended pre-phase therapy for a large mediastinal tumor PATIENT CHARACTERISTICS: * No known hypersensitivity or contraindication to study drugs * No other current malignancy * No severe concurrent disease (e.g., immune deficiency syndrome) * Not pregnant or nursing * Fertile patients must use effective contraception during and for up to 1 year after completion of study treatment * No known HIV positivity PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior chemotherapy or radiotherapy * At least 30 days since prior and no other concurrent investigational drugs or participation in another investigational trial

What they're measuring

Event-free survival

Timeframe: 5 years

Trial details

NCT IDNCT00433459

SponsorChristine Mauz-Körholz

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-01

View on ClinicalTrials.gov More Lymphoma trials